BioElectronics Corporation Introduces Its New Eye Surgery Recovery Mask
Posted on: Friday, 27 April 2007, 15:00 CDT
FREDERICK, Md., April 27 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (BIEL), announces that its specially designed eye mask for placement of ActiPatch Therapy after blepharoplasty surgery is now available. The mask, made of a soft and comfortable breathable fabric has a pocket on each side that holds a crescent shaped ActiPatch to assure proper placement of therapy over each eye. The unique design allows a patient to continue their normal activities during daytime treatment. At night, the patient can then move the mask over the eyes to receive treatment on both the upper and lower lids while sleeping.
"We believe that providing a simple way to place the therapy in the desired area without the use of adhesive will simplify post surgical care for both the patient and the recovery staff, said Lauren Jarman. Ms. Jarman is the designer of the mask.
The Company has also recently introduced new products including a head band for face lift healing therapy, a breast wrap, and a multi purpose wrap for pharmacy sales.
ActiPatch has been clinically proven to reduce swelling and bruising up to 50%. Plastic surgeons who are currently using ActiPatch have noted that in addition to their patients healing faster, the need for pain medication has been drastically reduced.
ActiPatch(TM) is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.
For more information visit http://www.bioelectronicscorp.com/. Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
BioElectronics Corporation
CONTACT: Andrew J. Whelan, President & CEO of BioElectronicsCorporation, +1-866-757-2284, +1-301-874-4890, Andrew.Whelan@Actipatch.net
Web site: http://www.bioelectronicscorp.com/
Source: PRNewswire-FirstCall
Related Articles
- Alternative Therapy for Patients at Risk for Stroke
- FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
- Published Study Demonstrates Effectiveness of VitalStim Therapy for Patients Suffering With Dysphagia
- Study Suggests Survival Benefit From Radioactive Microsphere Therapy in Patients With Colorectal Cancer Liver Metastases Who Have Failed Chemotherapy
- Study Shows Privigen(TM)10% Liquid Immunoglobulin Preparation for Intravenous Use, Is an Effective Replacement Therapy in Patients With Primary Immune Deficiencies
- Mirixa Corporation Enables Community Pharmacies to Deliver Over 70,000 Medication Therapy Management Patient Services
- Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
- Phase 2 Clinical Results of Ganite(R) Plus Standard Therapy in Patients With Relapsed/Refractory Lymphoma Presented at ASCO
- New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
- EPIC(3) Study Shows High Rate of Early Virological Response to Retreatment With PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C
 |
 |
User Comments (0)
RSS Feeds